NanJing Pharmaceutical Co Ltd
SSE:600713
NanJing Pharmaceutical Co Ltd
SSE:600713
Price:
4.86 CNY
1.89%
Market Closed
Updated:
May 3, 2024
NanJing Pharmaceutical Co Ltd
Net Income (Common)
|
NanJing Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Comparables:
1099
S
601607
600998
C
600511
000963
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
NanJing Pharmaceutical Co Ltd
SSE:600713
|
Net Income (Common)
¥565.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
32%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Net Income (Common)
¥8.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Net Income (Common)
¥3.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Net Income (Common)
¥2.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Net Income (Common)
¥2.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Net Income (Common)
¥2.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
See Also
What is NanJing Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
565.7m
CNY
565.7m
CNY
Based on the financial report for Sep 30, 2023, NanJing Pharmaceutical Co Ltd's Net Income (Common) amounts to 565.7m CNY.
What is NanJing Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
32%
32%
Over the last year, the Net Income (Common) growth was -10%. The average annual Net Income (Common) growth rates for NanJing Pharmaceutical Co Ltd have been 19% over the past three years , 17% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet
